Cancer patient gets new lease on life through clinical trial

April 30, 2012, Translational Genomics Research Institute

Arizona resident Evelyn Sorensen is in a far different place today than she was six months ago, thanks to a cutting-edge cancer clinical trial being conducted at the Virginia G. Piper Cancer Center at Scottsdale Healthcare in partnership with the Translational Genomics Research Institute (TGen).

When Sorensen was diagnosed with stage two two years ago, she underwent rounds of chemotherapy and . But the cancer eventually spread to her . Doctors told her they were inoperable, and there were no other standard treatment options available to her.

“I was out of options, and I wasn’t happy to hear that,” said Sorensen, a resident of Mesa. “I’m 47 years old and I’m not ready to say goodbye just yet.”

Sorensen then learned of the BIND-014 clinical trial being conducted through Virginia G. Piper Cancer Center , and quickly joined the study in August of 2011. Virginia G. Piper Cancer Center Clinical Trials is a partnership between Scottsdale Healthcare and TGen that treats cancer patients with promising new drugs.

BIND-014, created by BIND Biosciences in Cambridge, Mass., is being studied in patients with advanced or metastatic cancer. It uses microscopic drones to deliver medicine directly to cancer cells, increasing the drug’s effectiveness and minimizing side effects. The study is led in Scottsdale by Dr. Daniel Von Hoff, chief scientific officer at Scottsdale Healthcare and physician-in-chief at .

After her first treatment on the study in September 2011, Sorensen’s tumors began to shrink rapidly. Today, doctors say her cancer has diminished substantially, although she still takes the medication to maintain the results. Sorensen is beyond thrilled with the outcomes.

“I didn’t even have any of the horrible side effects that are associated with such as weight loss or hair loss,” she said. “I even joked with Dr. Von Hoff that I thought he was giving me a placebo because I didn’t feel anything!”

Scientists and oncologists say this new nanoparticle treatment could be a big step in the fight against cancer and have high hopes for the future of this kind of targeted therapy.

“Cancer cells are very good at erecting a defense against foreign harmful substances,” said Dr. Ramesh Ramanthan, M.D., medical director of Virginia G. Piper Clinical Trials. “We think that nanoparticles may be the solution to penetrating cancer cells and delivering drugs more effectively.”

As for Sorensen, the future is looking much brighter than it did for her six months ago. She is now strong enough to return to work and is back to swimming and enjoying her life.

“It’s so hard to explain because at one moment you’re trying to get your affairs in order and you only have a year to live, and then all of the sudden you are offered hope, a chance to live,” said Sorensen. “And I intend to take advantage of every moment of it.”

Explore further: TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

Related Stories

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

July 20, 2011
A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation ...

FDA approves new skin cancer drug

February 1, 2012
A new skin cancer drug tested for the first time in the world five years ago at the Virginia G. Piper Cancer Center at Scottsdale Healthcare just received expedited approval by the U.S. Food and Drug Administration, a remarkable ...

Results of new drug for pancreatic cancer patients published

October 4, 2011
Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new ...

'Seena' clinical trials named for pancreatic cancer advocate

December 1, 2011
A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.